Potential for Therapeutic Gain - 29 MeV Neutrons versus 6 MeV Neutrons

Abstract:

When a cancer type proves to be radioresistant to treatment with X-rays, the use of neutrons may constitute therapeutic gain provided the cells are relatively sensitive to high-LET radiation. In this work studies with different tumor cell types are reported following exposure to either photons or different neutron energies used in clinical radiation therapy. Potential for therapeutic gain is clearly noted for neutrons with a mean energy of 6 MeV whilst that for 29 MeV neutrons is dependent on the cell types used in the study.

• Periodical: Advanced Materials Research (Volume 1084)
• Pages: 559-566
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.1084.559
• Online since: January 2015
• Authors: Jacobus Slabbert*, Anne Vral
• Keywords: Cellular Radiosensitivity, Fast Neutrons, Relative Biological Effectiveness (RBE)

References

[1] A. Wambersie, G.W. Barendsen, N. Breteau, Overview and prospects of the application of fast neutrons in cancer therapy, J Eur Radiother 5 (1984) 248-264.

[2] J.J. Battermann, K. Breur, G.A. M Hart, Observations on pulmonary metastases in patients after single doses and multiple fractions of fast neutrons and cobalt-60 gamma rays, Eur J Cancer. 17 (1981) 539-548.

DOI: 10.1016/0014-2964(81)90056-6

[3] G. Schmitt, A. Wambersie, Review of the clinical results of fast neutron therapy, Radiother Onkol 17 (1990) 47-57.

[4] E.J. Hall, Radiobiological intercomparisons in vivo and in vitro, Int J Radiat Oncol Biol Phys. 3 (1977) 195-201.

[5] G.E. Laramore, J.T. Griffith, M. Boespflug, Fast neutron radiotherapy for sarcomas of soft tissue, bone and cartilage, Am J Clin Oncol. 12 (1989) 320 –326.

DOI: 10.1097/00000421-198908000-00009

[6] C. Stannard, F. Vernimmen, D. Jones, Neutron Therapy Program at the National Accelerator Centre, South Africa: Preliminary results, Radiat Oncol Invest. 2 (1995) 225-245.

[7] D. Van Beuningen, C. Streffer, H. Dellmann, Dünndarmschüden und Überleben von Mausen nach fraktionierten und einmaliger Röntgen –und Neutronenbestrahlung, Strahlenther Onkol. 157 (1981) 753-758.

[8] D. Van Beuningen, C. Streffer, G. Berthold, Mikronukleusbildung im Vergleich zür Überlebensrate von Menschlichen Melanoomzellen nach Röntgen -Neutronenbestrahlung und Hyperthermie, Strahlenther Onkol. 157 (1981) 600-606.

[9] B.J. Mijnheer, P. Wootton, J. R Williams, Uniformity in dosimetry protocols for therapeutic applications of fast neutron beams, Med Phys. 14 (1987) 1020-1026.

DOI: 10.1118/1.595980

[10] W. Sauerwein, W. Ziegler, K. Olthoff, et al. Neutron capture therapy using a fast neutron beam: Clinical considerations and physical aspects, Strahlenther Onkol. 165 (1989) 208–210.

[11] L. Van Wijk, C. Stannard, C.V. Levine, et al. Neutron irradiation of uterine sarcomas, Radiat Oncol Invest. 4 (1996) 275–280.

DOI: 10.1002/(sici)1520-6823(1996)4:6<275::aid-roi5>3.0.co;2-v

[12] D.H. Hussey, R. Meyn, J.B. Smathers, Neutron therapy. In: Bleehen NM, Galstein E, Haybittle JL, editors. Radiation therapy planning, New York: Marcel Dekker (1983) pp.393-437.

[13] G.E. Laramore, J.M. Krall, T.W. Griffin, et al. Neutron versus photon irradiation for irresectable salivary gland tumours: Final report of an RTOG-MRC randomized clinical trial, Int J Radiat Oncol Biol Phys. 27 (1993) 235-240.

DOI: 10.1016/0360-3016(93)90233-l

[14] G.W. Barendsen, J.J. Broerse, Differences in radiosensitivity of cells of various types of experimental tumors in relation to the RBE of 15 MeV neutrons, lnt. J. Radiat. Oncol. Biol. Phys. 3 (1977) 211-214.

DOI: 10.1016/0360-3016(77)90251-6

[15] J.D. Chapman, Biophysical models of mammalian cell inactivation by radiation. In: Meyn R.H. Withers H. R. (eds. ): Radiation biology in cancer research, Raven Press. New York (1988) 21-31.

[16] P.J. Binns, J.H. Hough JH. Lineal energy measurements in two fast neutron beams: d(16)/Be and p(66)/Be, Radiat Prot Dosim. 23 (1988) 385–388.

DOI: 10.1093/rpd/23.1-4.385

[17] B. Fertil, P.J. Deschavanne, J. Gueuletle, A. Possoz, A. Wambersie, E.P. Malaise, In vitro radiation of six human cell lines. II. Relation to RBE of 50 MeV neutrons, Radiat. Res. 1982, 90 526-537.

DOI: 10.2307/3575730

[18] R.A. Britten, H. M Warenius, C. Parkins, J.H. Peacock, The inherent cellular sensitivity to p(62. 5)/Be neutrons of human cells differing in photon sensitivity, Int J Radiat. Oncol. Biol. Phys. 61 (1992) 805–812.

DOI: 10.1080/09553009214551681

[19] H. M Warenius, R.A. Britten, P.G. Browning, I.E. Morton, J.H. Peacock, Identification of human in vitro cell lines with greater intrinsic cellular radiosensitivity tp 62. 5 MeV (p/Be) neutrons than 4 MeV photons, Int. J. Radiation. Oncol. Biol. Phys. 28 (1994).

DOI: 10.1016/0360-3016(94)90112-0

[20] J.P. Slabbert, T. Theron, F. Zölzer, C. Streffer, L. Böhm, A comparison of the potential therapeutic gain p(66)/Be neutrons and d(14)/Be neutrons, Int. J. Radiation Oncology Biol. Phys. 47 (2000) 1059-1065.

DOI: 10.1016/s0360-3016(00)00508-3

[21] A.M. Kellerer, O. Hug, A theory of dose-effect relations, Encyclop. Med. Radiol. III (1972) 1-42.

[22] B. Fertil, H. Dertinger, A. Courdi, E.P. Malais, Mean inactivation dose: a useful concept for intercomparison of human cell survival curves, Radiation Res. 99 (1984) 73-84.

DOI: 10.2307/3576448

[23] J.P. Slabbert, T. Theron, A. Serafin, D.T.L. Jones, L. Böhm, G. Schmitt, Radiosensitivity variations in human tumour cell lines exposed in vitro to p(66)/Be neutrons or 60Co-γ-rays, Strahlenther und Onkol. 172 (1996) 567–572.

[24] E.R. Hering, An investigation of changes in relative biological effectiveness (RBE) with depth for X-ray beams generated between 100 and 250 kVp using the mouse foot as the biological test system. Int J Radiat Oncol Biol Phys. 12 (1986) 815–821.

DOI: 10.1016/0360-3016(86)90041-6

[25] M.R. Raju, Heavy particle radiotherapy. New York: Academic Press. (1980) p.39–72.

[26] M. Tubiana, J. Dutreix, A. Wambersie, Introduction to radiobiology. London: Taylor & Francis; (1990) p.273–301.

[27] C. Stannard, F. Vernimmen, H. Carrara, D. Jones, S. Fredericks, J. Hille, E. de Kock, Malignant salivary gland tumours: can fast neutron therapy results point the way to carbon ion therapy?, Radiother Oncol. 109 (2013) 262-268.

DOI: 10.1016/j.radonc.2013.08.013

[28] J.P. Slabbert, L. August, A. Vral, J. Symons, The relative biological effectiveness of a high energy neutron beam for micronuclei induction in T-lymphocytes of different individuals, Radiation Measurements. 45 (2010) 1455-1457.

DOI: 10.1016/j.radmeas.2010.06.060

[29] T. Theron, J.P. Slabbert, A. Serafin, L. Böhm, The merits of cell kinetic parameters for the assessment of intrinsic cellular radiosensitivity to photon and high linear energy transfer neutron irradiation, Int J Radiat Oncol Biol Phys. 37 (1997).

DOI: 10.1016/s0360-3016(96)00533-0

[30] J.P. Slabbert, J.H. Langenhoven, B.S. Smit, Synthesis of [123I] iodoantipyrine to study the high-LET characteristics of Auger electrons in mammalian cells, Journal of Radioanalytical and Nuclear Chemistry. 240 (1999) 505-508.

DOI: 10.1007/bf02349403

[31] L. Böhm, G. Blekkenhorst, J.P. Slabbert, RBE and OER measurements on the p(66)/Be neutron beam at Faure, South Africa, Strahlenther Onkol. 168 (1992) 42-47.

[32] V. Vandersickel, P. Beukes, B. Van Bockstaele, J. Depuydt, A. Vral, J.P. Slabbert, Induction and disappearance of γH2AX foci and formation of micronuclei after exposure of human lymphocytes to 60Co γ-rays and p(66)+ Be(40) neutrons, Int J. Radiat Biol. 90 (2014).

DOI: 10.3109/09553002.2014.860252